The Fast Money traders take a look at today's biggest market movers.» Read More
It's not just what's heard, it's what's seen at the security check lines at Davos.
I need a break from blogging all-things Pfizer. Sequenom to the rescue with more data on its diagnostic test for Down Syndrome. Out of nearly 900 women there were no false negatives, but for the first time SQNM reported one false positive.
Despite the turmoil in the auto industry, AutoNation is out with better-than-expected results. The auto retailer posted fourth quarter earnings of $0.12 a share, beating Wall Street expectations by a penny.
Any time a company burns through 59 million dollars in cash every day, it's not good. But for Ford, burning through $5.5 Billion in the fourth quarter is a huge improvement from burning 83 million dollars a day in the third quarter.
Investors have to cover both sides of the ball, so to speak, if they want to make money in this market.
Step aside and take solace, John Thain: The public flogging you just endured for spending $1.2 million to jazz up your now-vacant office at Merrill Lynch could subside once the sanctimonious mob moves on to other Wall Street titans who would dare redecorate their digs.
More spending, whether it comes from individuals, businesses or the government, helps create jobs and get us out of this recession. It doesn't really matter what that spending is on as long as money circulates.
CEOs and other executives at the World Economic Forum in Davos, Switzerland, shared their insight on the financial crisis, the markets and the economy with CNBC.
The editorial board of "The Wall Street Journal" weighs in today on the Pfizer-Wyeth deal. The opinion piece details all of the well-documented problems facing big pharma and—perhaps not surprisingly coming from the WSJ editorial page—blames Washington for many of them.
It's amazing how much damage one man can do in such a short period of time.
For some reason this classic recession play isn't working right now. Cramer finds out why.
Before the official conference call began, an investor relations executive went through a laundry list of risk factors facing the company, including the possibility of a takeover or partnership, shareholder litigation, macro economic forces that could lead to unforeseen negative circumstances and so many others.
Reporters could only listen to Pfizer's hastily-organized "Investor Luncheon," so I can't tell you how many people showed up or what the room looked like. But Chairman and CEO Jeff Kindler drew a pretty good picture at the start of his opening remarks.
We are seeing an absolute lack of leadership from our current CEO ranks. I’d give our “C” level executives a “D-” for how they are responding to the current crisis.
This is the first paragraph/short story.
New York Attorney General Andrew Cuomo has subpoenaed former Merrill Lynch CEO John Thain over $4 billion in bonuses paid to Merrill executives, sources tell CNBC.
Yahoo investors are preparing for the worst and hoping for the best, but those hopes are dim for any good news after the bell tonight when the company reports its fourth quarter earnings.
Dow Chemical CEO Andrew Liveris still hopes his company can acquire specialty-chemical producer Rohm & Haas, despite some serious obstacles that have forced Dow to put the deal on hold.
Should the SEC be hounding Apple about the CEO's health disclosures when there are so many other things wrong with Wall Street?